Literature DB >> 9199754

Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL.

D H Fowler1, J Breglio, G Nagel, C Hirose, R E Gress.   

Abstract

Donor CD4+ and CD8+ T cells mediate graft-vs.-leukemia (GVL) responses in the allogeneic bone marrow transplantation (alloBMT) setting. To evaluate the role of functional T cell subsets in the mediation of GVL, alloreactive donor CD4+ (Th1/Th2) and CD8+ (Tc1/Tc2) T cells of defined cytokine phenotype were generated by in vitro culture. A leukemia/transplantation model (B6 into B6C3F1; 1050 cGy host irradiation) was established using the bcr/abl-transfected myeloid leukemia line, 32Dp210 (P210; H-2k). Leukemia control mice (1X10(4) P210 cells per recipient) died at day 12.0 post-BMT. Recipients of the CD4+, Th1-type or CD8+, Tc1-type populations were conferred a survival advantage (death at 20.7 and 23.5 days post-BMT, respectively). In contrast, the CD4+, Th2-type population did not mediate GVL (death at 12.3 days). Furthermore, cell mixing experiments demonstrated that the Th2 subset abrogated both Th1- and Tc1-mediated GVL. The CD8+, Tc2 population, which secreted type II cytokines and lysed the P210 leukemia target in vitro, mediated GVL in some experiments; interestingly, the magnitude of Tc2-mediated GVL was inversely related to the level of interleukin-10 (IL-10) secreted in vitro by the Tc2 population. These studies therefore indicate that alloreactive T cells of type I phenotype maximally generate GVL, and that type I/type II interactions are an important consideration for allogeneic transplantation in the setting of leukemic hosts.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9199754

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  10 in total

1.  Harnessing autophagy for adoptive T-cell therapy.

Authors:  Shoba Amarnath; Daniel H Fowler
Journal:  Immunotherapy       Date:  2012-01       Impact factor: 4.196

2.  Comparison of Wilms' tumor antigen 1-specific T lymphocyte generation soon after nonmyeloablative allergenic stem-cell transplantation in acute and chronic leukemia patients.

Authors:  Li Wei; HongLi Zuo; XueDong Sun; TieQiang Liu; Mei Guo; GuangXian Liu; QiYun Sun; JianHui Qiao; DanHong Wang; ChangLin Yu; KaiXun Hu; Zheng Dong; HuiSheng Ai
Journal:  Int J Hematol       Date:  2010-04-08       Impact factor: 2.490

3.  Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer.

Authors:  Nancy M Hardy; Miriam E Mossoba; Seth M Steinberg; Vicki Fellowes; Xiao-Yi Yan; Frances T Hakim; Rebecca R Babb; Daniele Avila; Juan Gea-Banacloche; Claude Sportès; Bruce L Levine; Carl H June; Hahn M Khuu; Ashley E Carpenter; Michael C Krumlauf; Andrew J Dwyer; Ronald E Gress; Daniel H Fowler; Michael R Bishop
Journal:  Clin Cancer Res       Date:  2011-09-26       Impact factor: 12.531

Review 4.  Prevention of GVHD without losing GVL effect: windows of opportunity.

Authors:  Ping Zhang; Benny J Chen; Nelson J Chao
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

Review 5.  Cytokines in graft-versus-host disease and the graft-versus-leukemia reaction.

Authors:  H J Deeg
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

Review 6.  Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

Authors:  Jian-Ming Li; Cynthia R Giver; Ying Lu; Mohammad S Hossain; Mojtaba Akhtari; Edmund K Waller
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

7.  Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells.

Authors:  Mark P Rubinstein; Ee Wern Su; Samantha Suriano; Colleen A Cloud; Kristina Andrijauskaite; Pravin Kesarwani; Kristina M Schwartz; Katelyn M Williams; C Bryce Johnson; Mingli Li; Gina M Scurti; Mohamed L Salem; Chrystal M Paulos; Elizabeth Garrett-Mayer; Shikhar Mehrotra; David J Cole
Journal:  Cancer Immunol Immunother       Date:  2015-02-13       Impact factor: 6.968

8.  Memory CD4+ T cells do not induce graft-versus-host disease.

Authors:  Britt E Anderson; Jennifer McNiff; Jun Yan; Hester Doyle; Mark Mamula; Mark J Shlomchik; Warren D Shlomchik
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

9.  Allogeneic Th1 cells home to host bone marrow and spleen and mediate IFNγ-dependent aplasia.

Authors:  Joseph H Chewning; Weiwei Zhang; David A Randolph; C Scott Swindle; Trenton R Schoeb; Casey T Weaver
Journal:  Biol Blood Marrow Transplant       Date:  2013-03-21       Impact factor: 5.742

10.  Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells.

Authors:  Jason E Foley; Jacopo Mariotti; Kaitlyn Ryan; Michael Eckhaus; Daniel H Fowler
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.